FDA expands Jaypirca approval to first-line treatment of CLL and SLL
The FDA has moved Jaypirca into first-line CLL and SLL treatment following Phase III data showing a substantial reduction in the risk of disease progression or death.
Jaypirca (pirtobrutinib) is now approved for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion.
In BRUIN CLL-313, median progression-free survival was not reached with Jaypirca compared with 33.5 months for bendamustine plus rituximab, corresponding to a hazard ratio of 0.20.
Field | Content |
Article Type | Approvals |
Drug Name | Pirtobrutinib |
Brand Name | Jaypirca |
Company | Eli Lilly and Company |
Regulatory Authority | U.S. Food and Drug Administration |
Approval Type | Indication expansion to first-line treatment |
Indication | Previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion |
Patient Population | Adults |
Therapy Areas | Oncology; haematology |
Technology/Modality | Non-covalent BTK inhibitor |
Clinical Study | Phase III BRUIN CLL-313 |
Key Result | Median progression-free survival was not reached with Jaypirca versus 33.5 months with bendamustine plus rituximab; hazard ratio 0.20 |
Geography | United States |
What Happened | The FDA expanded Jaypirca's indication to include first-line treatment of eligible adults with previously untreated CLL or SLL. |
Why It Matters | The decision moves the first and only approved non-covalent BTK inhibitor into an earlier treatment setting for CLL and SLL. |
Supporting Context | The approval was supported by Phase III BRUIN CLL-313 data demonstrating a substantial reduction in the risk of progression or death versus bendamustine plus rituximab. |
Potential Impact | The expanded label gives clinicians another targeted first-line treatment option for eligible patients with CLL or SLL. |
Key Takeaway | Jaypirca is now FDA approved for certain previously untreated CLL and SLL patients. |
What to Watch | First-line uptake, treatment sequencing with covalent BTK inhibitors and longer-term survival data. |
Primary Source | U.S. Food and Drug Administration |
Relevant Date | 2 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
留言